21.37
-0.92 (-4.13%)
| Previous Close | 22.29 |
| Open | 22.31 |
| Volume | 604,741 |
| Avg. Volume (3M) | 812,482 |
| Market Cap | 1,146,156,544 |
| Price / Sales | 3.02 |
| Price / Book | 2.60 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 |
| Profit Margin | 15.74% |
| Operating Margin (TTM) | -22.98% |
| Diluted EPS (TTM) | 0.930 |
| Quarterly Revenue Growth (YOY) | 32.00% |
| Total Debt/Equity (MRQ) | 7.50% |
| Current Ratio (MRQ) | 3.94 |
| Operating Cash Flow (TTM) | 38.05 M |
| Levered Free Cash Flow (TTM) | 44.34 M |
| Return on Assets (TTM) | -7.01% |
| Return on Equity (TTM) | 16.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | CareDx, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 95.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Stephens & Co., 87.18%) | Buy |
| Median | 26.00 (21.67%) | |
| Low | 25.00 (HC Wainwright & Co., 16.99%) | Hold |
| Average | 30.33 (41.93%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 19.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 26.00 (21.67%) | Buy | 17.62 |
| HC Wainwright & Co. | 03 Mar 2025 | 25.00 (16.99%) | Hold | 21.13 |
| Stephens & Co. | 27 Feb 2025 | 40.00 (87.18%) | Buy | 21.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |